Pyruvate preparation for treating non-small cell lung cancer and preparation method thereof
By developing a pyruvate preparation containing a special synergist, the problem of limited efficacy in the treatment of non-small cell lung cancer has been solved, effectively inhibiting non-small cell lung cancer cells and selective EGFR degradation are achieved, and the therapeutic effect is significantly improved.
CN119745884AActive Publication Date: 2025-04-04JIANG SU PHARMAMAXCORP
2 Cites 1 Cited by
Patent Information
- Application Number
- CN202510252520.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-05
- Publication Date
- 2025-04-04
- Estimated Expiration
- 2045-03-05
AI Technical Summary
Technical Problem
The prior art has limited efficacy in the treatment of non-small cell lung cancer, especially the effect of targeted treatment on improving overall survival time is not good.
Method used
A pyruvate preparation, including sodium pyruvate and a special synergist prepared by a multi-step reaction, has significant anti-tumor effect.
Benefits of technology
This pyruvate preparation significantly inhibits the proliferation of non-small cell lung cancer cells, especially has a selective degradation effect on EGFR protein expression, improving the efficacy of the treatment and reducing toxicity.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention belongs to the technical field of biological medicines, and particularly relates to a pyruvate preparation for treating non-small cell lung cancer and a preparation method of the pyruvate preparation. The pyruvate preparation is prepared from the following components in parts by weight: 0.03 to 0.05 part of sodium pyruvate, 0.01 to 0.03 part of synergist and 100 parts of water for injection. The preparation method of the synergist comprises the following steps: adding sodium pyruvate into a 3, 4-diaminophenol solution for reaction to obtain an intermediate 1; reacting the intermediate 1 with 4-chloro-1, 2-phenylenediamine to obtain an intermediate 2; reacting p-hydroxybenzaldehyde with propynyl chloride to obtain an intermediate 3; reacting the intermediate 3 with 1-azido-4-chlorobenzene to obtain an intermediate 4; and reacting the intermediate 2 with the intermediate 4 to obtain the synergist. Experimental results show that the synergistic agent and the sodium pyruvate are matched to achieve an excellent anti-tumor effect, and particularly, the selectivity of inhibition on non-small cell lung cancer tumors is shown.
Need to check novelty before this filing date? Find Prior Art